Small Cell Transformation and T790M Mutation as
Coresistance Mechanisms for First-line Epidermal
Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure

QR Code

Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First-line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure

Discovery of the activating EGFR mutation gene has revolutionized the treatment of patients with NSCLC. Nevertheless, resistance to first-line EGFR tyrosine kinase inhibitors (TKIs) develops in most patients with EGFR-mutant NSCLC after a period of 9 to 13 months. Here, we reported a case of fi...

Full description

Bibliographic Details
Main Author:	Chee, Shee Chai
Format:	Article
Language:	English
Published:	Elsevier Inc. 2017
Subjects:	R Medicine (General)
Online Access:	http://ir.unimas.my/id/eprint/19173/ http://ir.unimas.my/id/eprint/19173/7/Small%20Cell.pdf

Similar Items

Characteristics of epidermal growth factor receptor (EGFR)-Mutated Non Small Cell Lung Carcinoma (NSCLC)-patients who developed resistance to first or second generation Egfrtyrosine Kinase Inhibitor (TKI) Therapy through T790M mutation / Vijayan Munusamy
by: Vijayan, Munusamy
Published: (2017)

Resistance mechanisms causing first-line epidermal growth factor receptor-tyrosine kinase inhibitor treatment failure
by: Chai, C.S., et al.
Published: (2017)

EGFR-directed tyrosine kinase inhibitors for non-small cell lung cancer
by: Fatin Nur Elyana Mohd Sidek,, et al.
Published: (2025)

An investigation into the effects of the epidermal growth factor receptor tyrosine kinase inhibitor "Gefitinib" on human breast cancer
by: Gutteridge, Eleanor
Published: (2010)

Case Series of Small Cell Lung Cancer Transformation as Resistance Mechanism to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
by: Liam, C, et al.
Published: (2017)

Outcome of patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors versus cytotoxic chemotherapy
by: Chai, Chee She
Published: (2015)

Molecular docking analysis on the designed benzimidazole derivatives as EGFR inhibitors: comparison between EGFR wild-type (EGFRWT) and T790M mutant
by: Nurul Awani Syazzira Jalil,, et al.
Published: (2023)

Epidermal growth factor receptor (EGFR) mutations are the main oncogenic driver mutation in adenocarcinoma in never-smokers - findings from the emlan study
by: Liam, Chong Kin, et al.
Published: (2012)

Case series of small cell lung cancer transformation post tyrosine kinase inhibitor failure
by: Chai, C.S., et al.
Published: (2017)

Benzalhydantoin derivative-based inhibitors of eight receptor tyrosine kinases: synthesis, in-vitro, and in-silico study
by: Muhammad Naufal,, et al.
Published: (2025)

Epidermal Growth Factor Receptor Mutation in Newly Diagnosed Lung Adenocarcinoma
by: Chee, Shee Chai, et al.
Published: (2017)

Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats
by: Carter, Joanne J., et al.
Published: (2016)

Linifanib – a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator
by: Marlow, Maria, et al.
Published: (2015)

Self-assembling tyrosine kinase inhibitors for localised targeted delivery
by: Al-Ameedee, Mohammed
Published: (2017)

An apoferritin-based drug delivery system for the tyrosine kinase inhibitor gefitinib
by: Kuruppu, Anchala I., et al.
Published: (2015)

Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?
by: Hamdi, Amir Imran Faisal, et al.
Published: (2022)

Detection of Isocitrate Dehydrogenase (IDH-1), Epidermal Growth Factor Receptor (EGFR), P53 and C-erbB2/HER2 mutation in glial tumour
by: Azman, Nusaibah, et al.
Published: (2022)

Real-time analysis of the binding of fluorescent VEGF₁₆₅a to VEGFR2 in living cells: Effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes
by: Kilpatrick, Laura E., et al.
Published: (2017)

Determination of gene expression of tyrosine kinase receptors (HER family) in FFPE tissue of colorectal adenocarcinoma
by: Othman @ Jaffar, Rosfayati, et al.
Published: (2015)

Sulfated galactans from red seaweed Gracilaria fisheri target epidermal growth factor receptor (EGFR) and inhibit cholangiocarcinoma cells (CCA) proliferation
by: Sae-lao, Thannich, et al.
Published: (2017)

Spectroscopic and molecular modeling studies on the interaction of tyrosine kinase inhibitors with human serum albumin / Md. Zahirul Kabir
by: Md. Zahirul , Kabir
Published: (2018)

Effects of receptor tyrosine kinase inhibitors on VEGF165a- and VEGF165b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2
by: Carter, Joanne J., et al.
Published: (2015)

Identification of a novel invariant splice site mutation of Bruton's tyrosine kinase (BTK) gene in a Malaysian family with X-linked agammaglobulinemia / Chear Chai Teng
by: Chear, Chai Teng
Published: (2014)

Survival rate and prognostic factors of survival among chronic myeloid leukaemia adults after initiation of tyrosine kinase inhibitor therapy in Hospital Ampang, Selangor
by: Ali, Zakiah Bakar
Published: (2024)

Huge relief for 790 varsity students
by: Rajaendram, Rebecca, et al.
Published: (2020)

A prospective study on epidermal growth factor receptor mutations in non-small cell lung cancer in Malaysian patients
by: Liam, C K, et al.
Published: (2012)

Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic Malaysian patient population
by: Liam, Chong-Kin, et al.
Published: (2014)

Around 790 IPT students return home
by: Birruntha, S.
Published: (2020)

Targeting the hypoxic expression of epidermal growth factor receptor
by: Alamoudi, Abdulmohsin
Published: (2021)

The Business Perspectives Strategy Towards the TKI (Indonesian Migrant Workers) Market
by: Sihombing, Haeryip, et al.
Published: (2011)

Detection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients
by: Ng, Tiffany Shi Yeen, et al.
Published: (2013)

Translational control of epidermal growth factor receptor in neurodegenerative diseases
by: Smalley, Daniel. S.
Published: (2017)

Role of Focal Adhesion Tyrosine Kinases in GPVI-Dependent Platelet Activation and Reactive Oxygen Species Formation
by: Carrim, N., et al.
Published: (2014)

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
by: Yu, Yu, et al.
Published: (2015)

The focal adhesion kinase Pyk2 links Ca2+ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets
by: Canobbio, I., et al.
Published: (2015)

A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: data from the British DESTINY study
by: Clark, Richard E., et al.
Published: (2017)

The proline-rich tyrosine kinase Pyk2 regulates platelet integrin aIIbß3 outside-in signaling
by: Cipolla, L., et al.
Published: (2013)

A randomized control trial comparing peginterferon-α-2a versus observation after stopping tyrosine kinase inhibitor in chronic myeloid leukemia with deep molecular response for at least two years
by: Kuan, Jew-Win, et al.
Published: (2016)

Inhibition of transforming growth factor-β via the activin receptor-like kinase-5 inhibitor attenuates pulmonary fibrosis
by: Koh, Rhun Yian, et al.
Published: (2015)

Editorial: Platelet hem-Immunoreceptor Tyrosine-Based Activation Motif Receptors: At Lease One Required
by: Berndt, Michael, et al.
Published: (2013)